Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

NCT05092386 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT05092386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 3, 2023
Completion date
May 28, 2024
Enrollment
310 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infections